$SUNPHARMA Industries Delivers Strong Q4 FY26 Results with 26% Profit Growth

$SUNPHARMA emerged as a key highlight in the Q4 earnings season, reporting a strong financial performance for the March quarter of FY26. The company posted a 26% year-on-year rise in consolidated net profit to ₹2,714 crore, supported by healthy double-digit growth in its India formulations business and innovative medicines segment. Q4 FY26 Financial Highlights Net Profit: Climbed nearly 26.2% YoY to ₹2,714.03 crore, compared with ₹2,149.88 crore in Q4 FY25. Revenue from Operations: Advanced 12.8% YoY to ₹14,612 crore. EBITDA: Increased 6.4% to ₹3,954 crore, with EBITDA margin standing at 27.1%. Dividend: The board proposed a final dividend of ₹5 per share, taking the total FY26 dividend payout to ₹16 per share. FY26 Annual Performance Net Profit: Expanded 5% year-on-year to ₹11,479 crore. Total Sales: Rose 11.9% to ₹58,220 crore. EBITDA: Surged 16.1% to ₹17,731 crore. The company’s quarterly and annual growth reflects sustained momentum across its domestic formulations business and specialty portfolio, reinforcing its strong operational performance during FY26. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.